Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research report report published on Wednesday. The firm issued a hold rating on the medical research company’s stock.

A number of other analysts also recently commented on the company. B. Riley reiterated a buy rating and issued a $3.00 price objective on shares of Cytosorbents in a research report on Wednesday, May 15th. HC Wainwright reissued a neutral rating and issued a $1.00 target price on shares of Cytosorbents in a report on Tuesday, May 7th.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $0.75 on Wednesday. The business has a 50 day moving average price of $0.87 and a 200 day moving average price of $1.02. Cytosorbents has a twelve month low of $0.75 and a twelve month high of $4.29. The company has a market cap of $40.90 million, a price-to-earnings ratio of -1.28 and a beta of 0.61. The company has a quick ratio of 1.21, a current ratio of 1.49 and a debt-to-equity ratio of 0.10.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Thursday, May 9th. The medical research company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. The company had revenue of $9.79 million during the quarter, compared to the consensus estimate of $9.78 million. During the same quarter last year, the company earned ($0.17) EPS. Research analysts predict that Cytosorbents will post -0.36 earnings per share for the current year.

Hedge Funds Weigh In On Cytosorbents

A number of hedge funds have recently modified their holdings of the stock. Skylands Capital LLC raised its holdings in shares of Cytosorbents by 10.5% in the 4th quarter. Skylands Capital LLC now owns 3,254,213 shares of the medical research company’s stock worth $3,612,000 after buying an additional 309,543 shares in the last quarter. Avenir Corp increased its holdings in Cytosorbents by 4.0% during the 1st quarter. Avenir Corp now owns 3,172,696 shares of the medical research company’s stock valued at $3,014,000 after purchasing an additional 121,294 shares in the last quarter. Neuberger Berman Group LLC increased its holdings in Cytosorbents by 19.9% during the 4th quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 299,103 shares in the last quarter. Sargent Investment Group LLC increased its holdings in Cytosorbents by 4.1% during the 4th quarter. Sargent Investment Group LLC now owns 1,308,747 shares of the medical research company’s stock valued at $1,453,000 after purchasing an additional 51,699 shares in the last quarter. Finally, CM Management LLC increased its holdings in Cytosorbents by 98.8% during the 1st quarter. CM Management LLC now owns 825,000 shares of the medical research company’s stock valued at $784,000 after purchasing an additional 410,000 shares in the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.